$EXEL News
Last published 1d ago
- 1d agoEXELStifel 2026 Healthcare Conference - EXELIXIS INCEarnings Call TranscriptsAnd glad to have with us to kick off the afternoon sessions, we have Andrew Peters from Exalexis. Andrew, thanks for joining us. Thanks for having us. Any opening statements you want to make before we jump into Q&A? Yeah
- 2d agoEXELGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - EXELIXIS INCEarnings Call Transcriptswith XLXs. With me today, I have Andrew Peters, Chief Strategy Officer. My name is Michael Schmidt, Biotech Analyst with Guggenheim, and I'm looking really forward to this. Welcome, Andrew. Thank you for having me. Andre
- 1w agoEXELEXELIXIS Q3 2026 FINANCIAL RESULTS CONFERENCE CALL - EXELIXIS INCEarnings Call TranscriptsGood day, ladies and gentlemen, and welcome to the Exelixis Third Quarter 2026 Financial Results Conference Call. My name is Tawanda, and I will be your operator for today. As a reminder, this call is being recorded for
- 2w agoEXELEXELIXIS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoEXELExelixis Announces Third Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire– Total Revenues of $658.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $604.9 million – – GAAP Diluted EPS of $0.85, Non-GAAP Diluted EPS of $0.94 – – Conference Call and Webcast Today at 5:00 PM
- 4w agoEXELExelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026Business Wire– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026,
- 4w agoEXELGMABONCYRVMD+1Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with
- 1mo agoEXELKuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to
- 1mo agoEXELExelixis, Inc. - 1773673 - EXELIXIS INCEarnings Call TranscriptsGood morning everyone, I'm Sean Laman, Head of US Mid-Cap Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, just to make you aware of some important disclosu
- 2mo agoEXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in SeptemberBusiness Wire– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells
- 2mo agoEXELExelixis Announces Update on Patent Litigation Trial Appeal with MSN LaboratoriesBusiness WireExelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the
- 2mo agoEXELKuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached ...
- 3mo agoEXELExelixis Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million - - GAAP Diluted EPS of $0.82, Non-GAAP Diluted EPS of $0.91 - - Conference Call and Webcast Today at 5:00 PM
- 3mo agoEXELExelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026Business Wire– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after
- 4mo agoEXELExelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal CancerBusiness WireExelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, NLM)
- 5mo agoEXELJefferies Global Healthcare Conference in New York - EXELIXIS INCEarnings Call TranscriptsWell, good morning, everyone. I really do appreciate it. My name is Akash Jawari. I head our permanent biotech efforts on the research side here at Jefferies, and I have the pleasure of hosting the ExoLexus management te
- 5mo agoEXELExelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026Business Wire– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo – Exelixis, Inc. (NASDAQ:EXEL) today
- 5mo agoEXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in JuneBusiness Wire- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026
- 5mo agoEXELExelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor TypesBusiness Wire– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced presentations for its flagship product, CABOMETYX®
- 5mo agoEXELExelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal CancerBusiness Wire– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company's subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – Exelixis, Inc. (NASDAQ:EXEL) today announced that
- 6mo agoEXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in MayBusiness Wire- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA
- 6mo agoEXELExelixis Q1 2026 Financial Results Conference Call - EXELIXIS INCEarnings Call TranscriptsGood day, ladies and gentlemen, and welcome to the Exelixis First Quarter 2026 Financial Results Conference Call. My name is Cherie, and I'll be your operator for today. As a reminder, this call is being recorded for rep
- 6mo agoEXELExelixis Announces First Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program
- 6mo agoEXELExelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026Business Wire– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the
- 8mo agoEXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in MarchBusiness Wire- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen
- 8mo agoONCYEXELLLYMRK+1Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the ChargePR NewswireUSA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion...
- 9mo agoEXELExelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate UpdateBusiness Wire– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025,
- 9mo agoEXELExelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal CancerBusiness Wire– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with
- 9mo agoEXELExelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026Business Wire– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday,
- 11mo agoAGENCRDFEXELGILD+1GI Cancer Immunotherapy Breakthroughs Signal New Treatment EraGlobeNewswireVANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last
- 11mo agoEXELExelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025Business Wire- Event to Review R&D Progress and Outline Exelixis' Strategy for Building Next-generation Oncology Franchises - Exelixis, Inc. (NASDAQ:EXEL) today announced that it will webcast its virtual event, Exelixis 2025
- 1y agoEXELExelixis Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for
- 1y agoEXELExelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025Business Wire– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after
- 1y agoONCZLABCRVSDNA+2The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive PartnersPR NewswireThe Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of...
- 1y agoAKROEXELLEGNSynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate ProgressGlobeNewswireDUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant
- 1y agoEXELExelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The LancetBusiness Wire– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat
- 1y agoEXELExelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025Business Wire– CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neuroendocrine tumors (NET) – – The lungs are the second most common NET site of origin, yet
- 1y agoEXELApproval of Cabometyx, Nda #208692 (Labeling)FDA Approved DrugsApproval Date: 10/09/2025; Drug Name: Cabometyx, Nda #208692; Active Ingredients: CABOZANTINIB S-MALATE; Company: Exelixis Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 208692
- 1y agoEXELApproval of Cometriq, Nda #203756 (Labeling)FDA Approved DrugsApproval Date: 10/09/2025; Drug Name: Cometriq, Nda #203756; Active Ingredients: CABOZANTINIB S-MALATE; Company: Exelixis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 203756
- 1y agoEXELExelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
- 1y agoEXELApproval of Cabometyx, Nda #208692 (Efficacy)FDA Approved DrugsApproval Date: 09/10/2025; Drug Name: Cabometyx, Nda #208692; Active Ingredients: CABOZANTINIB S-MALATE; Company: Exelixis Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 208692
- 1y agoEXELExelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoEXELExelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoEXELExelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoEXELExelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and DevelopmentBusiness Wire– Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed
- 1y agoEXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in SeptemberBusiness Wire– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: 2025
- 1y agoEXELExelixis, Inc. (EXEL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoEXELExelixis Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire- Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 - - Conference Call and Webcast Today at 5:00 PM
- 1y agoEXELExelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo – – CABOMETYX is
- 1y agoEXELExelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025Business Wire– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the